A Patient with AFP-Producing Gastric Cancer and Stenosis Who Regained Oral Intake Capabilities after T-DXd Treatment

Hiroyuki Amagai; Shinichi Sasagawa; Yoshio Koide; Soichiro Tsukamoto; Yukimasa Miyazawa; Hisami Yamakawa; Hirokazu Murayama; Takako Sentsui; Hisahiro Matsubara; Kazuto Yamazaki; Tsutomu Yarita

A Patient with AFP-Producing Gastric Cancer and Stenosis Who Regained Oral Intake Capabilities after T-DXd Treatment

Hiroyuki Amagai, Shinichi Sasagawa, Yoshio Koide, Soichiro Tsukamoto, Yukimasa Miyazawa, Hisami Yamakawa, Hirokazu Murayama, Takako Sentsui, Hisahiro Matsubara, Kazuto Yamazaki, Tsutomu Yarita

School of Medicine

Yarita Hospital

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

We present the case of a 55-year-old man with HER2-positive, AFP-producing gastric cancer and multiple liver metastases. The patient consequently underwent 7 courses of SOX plus trastuzumab therapy, 3 courses of weekly PTX plus ramucirumab therapy, and 3 courses of nivolumab therapy, all of which resulted in PD. Obstruction due to tumor growth became noticeable 9 months after the start of the first treatment. Subsequently, the patient experienced malnutrition and systemic edema due to impaired oral intake. However, subsequent trastuzumab deruxtecan(T-DXd)therapy induced remarkable tumor shrinkage. Furthermore, oral intake became possible, and edema started subsiding. Thus, we report the course of a patient with AFP-producing gastric cancer and stenosis who regained oral intake capabilities after T-DXd treatment.

Original language	English
Pages (from-to)	813-816
Number of pages	4
Journal	Japanese Journal of Cancer and Chemotherapy
Volume	50
Issue number	7
State	Published - 1 Jul 2023

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{908e723d5e9b47288207929895cb1bd8,

title = "A Patient with AFP-Producing Gastric Cancer and Stenosis Who Regained Oral Intake Capabilities after T-DXd Treatment",

abstract = "We present the case of a 55-year-old man with HER2-positive, AFP-producing gastric cancer and multiple liver metastases. The patient consequently underwent 7 courses of SOX plus trastuzumab therapy, 3 courses of weekly PTX plus ramucirumab therapy, and 3 courses of nivolumab therapy, all of which resulted in PD. Obstruction due to tumor growth became noticeable 9 months after the start of the first treatment. Subsequently, the patient experienced malnutrition and systemic edema due to impaired oral intake. However, subsequent trastuzumab deruxtecan(T-DXd)therapy induced remarkable tumor shrinkage. Furthermore, oral intake became possible, and edema started subsiding. Thus, we report the course of a patient with AFP-producing gastric cancer and stenosis who regained oral intake capabilities after T-DXd treatment.",

author = "Hiroyuki Amagai and Shinichi Sasagawa and Yoshio Koide and Soichiro Tsukamoto and Yukimasa Miyazawa and Hisami Yamakawa and Hirokazu Murayama and Takako Sentsui and Hisahiro Matsubara and Kazuto Yamazaki and Tsutomu Yarita",

year = "2023",

month = jul,

day = "1",

language = "英語",

volume = "50",

pages = "813--816",

journal = "Japanese Journal of Cancer and Chemotherapy",

issn = "0385-0684",

publisher = "Japanese Journal of Cancer and Chemotherapy Publishers Inc.",

number = "7",

}

TY - JOUR

T1 - A Patient with AFP-Producing Gastric Cancer and Stenosis Who Regained Oral Intake Capabilities after T-DXd Treatment

AU - Amagai, Hiroyuki

AU - Sasagawa, Shinichi

AU - Koide, Yoshio

AU - Tsukamoto, Soichiro

AU - Miyazawa, Yukimasa

AU - Yamakawa, Hisami

AU - Murayama, Hirokazu

AU - Sentsui, Takako

AU - Matsubara, Hisahiro

AU - Yamazaki, Kazuto

AU - Yarita, Tsutomu

PY - 2023/7/1

Y1 - 2023/7/1

N2 - We present the case of a 55-year-old man with HER2-positive, AFP-producing gastric cancer and multiple liver metastases. The patient consequently underwent 7 courses of SOX plus trastuzumab therapy, 3 courses of weekly PTX plus ramucirumab therapy, and 3 courses of nivolumab therapy, all of which resulted in PD. Obstruction due to tumor growth became noticeable 9 months after the start of the first treatment. Subsequently, the patient experienced malnutrition and systemic edema due to impaired oral intake. However, subsequent trastuzumab deruxtecan(T-DXd)therapy induced remarkable tumor shrinkage. Furthermore, oral intake became possible, and edema started subsiding. Thus, we report the course of a patient with AFP-producing gastric cancer and stenosis who regained oral intake capabilities after T-DXd treatment.

AB - We present the case of a 55-year-old man with HER2-positive, AFP-producing gastric cancer and multiple liver metastases. The patient consequently underwent 7 courses of SOX plus trastuzumab therapy, 3 courses of weekly PTX plus ramucirumab therapy, and 3 courses of nivolumab therapy, all of which resulted in PD. Obstruction due to tumor growth became noticeable 9 months after the start of the first treatment. Subsequently, the patient experienced malnutrition and systemic edema due to impaired oral intake. However, subsequent trastuzumab deruxtecan(T-DXd)therapy induced remarkable tumor shrinkage. Furthermore, oral intake became possible, and edema started subsiding. Thus, we report the course of a patient with AFP-producing gastric cancer and stenosis who regained oral intake capabilities after T-DXd treatment.

UR - https://www.scopus.com/pages/publications/85165876772

M3 - 記事

C2 - 37496227

AN - SCOPUS:85165876772

SN - 0385-0684

VL - 50

SP - 813

EP - 816

JO - Japanese Journal of Cancer and Chemotherapy

JF - Japanese Journal of Cancer and Chemotherapy

IS - 7

ER -

A Patient with AFP-Producing Gastric Cancer and Stenosis Who Regained Oral Intake Capabilities after T-DXd Treatment

Abstract

UN SDGs

Other files and links

Fingerprint

Cite this